Purple Biotech Ltd. PPBT
We take great care to ensure that the data presented and summarized in this overview for PURPLE BIOTECH LTD. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PPBT
View all-
Armistice Capital, LLC New York, NY2.12MShares$867,1500.02% of portfolio
-
Kingswood Wealth Advisors, LLC San Diego, CA186KShares$76,3010.01% of portfolio
-
Morgan Stanley New York, NY137KShares$56,0100.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il58KShares$23,7890.0% of portfolio
-
Xtx Topco LTD London, X029.1KShares$11,9300.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny21.4KShares$8,7890.0% of portfolio
-
Virtu Financial LLC New York, NY16.1KShares$6,5910.0% of portfolio
-
Venture Visionary Partners LLC15.6KShares$6,3760.0% of portfolio
-
Wealth Advisors Of Iowa, LLC14.3KShares$5,8500.01% of portfolio
-
Geode Capital Management, LLC Boston, MA12.7KShares$5,1930.0% of portfolio
Latest Institutional Activity in PPBT
Top Purchases
Top Sells
About PPBT
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Insider Transactions at PPBT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|